Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Federal Trade Commission
McKinsey
Citi
Julphar
QuintilesIMS

Generated: April 18, 2019

DrugPatentWatch Database Preview

Litigation Details for HOSPIRA, INC. v. SANDOZ INTERNATIONAL GmbH (D.N.J. 2009)

« Back to Dashboard

HOSPIRA, INC. v. SANDOZ INTERNATIONAL GmbH (D.N.J. 2009)

Docket ➤ Sign Up Date Filed 2009-09-04
Court District Court, D. New Jersey Date Terminated 2012-05-04
Cause 35:271 Patent Infringement Assigned To Mary Little Cooper
Jury Demand Defendant Referred To Magistrate Judge Tonianne J. B
Parties CARACO PHARMACEUTICAL LABORATORIES LTD; HOSPIRA, INC.; ORION CORPORATION; SANDOZ CANADA INC.; SANDOZ INTERNATIONAL GMBH; SANDOZ, INC.
Patents 4,910,214; 5,344,840; 6,716,867
Attorneys AGNIESZKA ANTONIAN; ERIC I. ABRAHAM; GREGORY D. MILLER; LIZA M. WALSH; NANCY ANN DEL PIZZO; THOMAS J. MELORO , JR.
Link to Docket External link to docket
Small Molecule Drugs cited in HOSPIRA, INC. v. SANDOZ INTERNATIONAL GmbH
The small molecule drug covered by the patents cited in this case is ➤ Sign Up .

Details for HOSPIRA, INC. v. SANDOZ INTERNATIONAL GmbH (D.N.J. 2009)

Date Filed Document No. Description Snippet Link To Document
2010-09-14 104 Brief invalidity contentions related to U.S. Patent No. 4,910,214 (the “’214 patent”). Defendants added 11 alleged …the Local Patent R.ules. A. chal Standards For Showing Good Cause. “Pursuant to Local Patent Rule 3.7,…invalidity contentions related to U.S. Patent No. 6,716,867 (the “’867 patent”). IJ\‘=t`endams__ t _1 None …the validity of the =214 patent under 35 U.s.c. § 112. _Defendanc had the patent, which is all they needed…Serving New Invalidity Contentions For The ’867 Patent ............................................... External link to document
2011-02-23 166 Redacted Document infringement of U.S. Patent Nos. 4,910,214 (the “’214 Patent”) and 6,716,867 (the “’867 Patent”; collectively…collectively with the ’214 Patent, the “Patents-In-Suit”) under 35 U.S.C. § 271(e), based on the filing of … during prosecution of both the ’214 Patent and the ’867 Patent. (See D.E. 9, Answer, Affirmative …Applicants for the ’214 Patent were aware, prior to the issuance of that patent, that these representations…Table 2 of the ’214 Patent and the arguments made in support of its patentability, [REDACTED] and thus External link to document
2011-02-23 167 Redacted Document the patents in suit. The patents in the case are U.S. Patent Nos. 4,910,214 (the “’214 Patent”), …they disclosed them to the Patent Office as they were required to do, the patents in suit would never … Waxman Act, involves a claim of patent infringement on patents relating to compound known as dexmedetomidine… ’214 Patent in view of evidence produced by Plaintiffs that refutes the claims of patentability Plaintiffs…Invalidity of the ’214 Patent. Sandoz Inc.’s initial contentions showed that the ’214 Patent, which claimed External link to document
2011-05-17 212 Stipulation and Order regarding infringement of certain claims of U.S. Patent No. 4,910,214. Signed by Magistrate Judge Tonianne J. …2009 4 May 2012 3:09-cv-04591-MLC-TJB Patent Defendant District Court, D. External link to document
2011-06-03 242 Certification in Opposition to Motion of Inequitable Conduct with Respect to U.S. Patent 6,716,867 of Kyle Mooney filed by SANDOZ CANADA INC.…2009 4 May 2012 3:09-cv-04591-MLC-TJB Patent Defendant District Court, D. External link to document
Date Filed Document No. Description Snippet Link To Document

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
US Department of Justice
Healthtrust
Accenture
Federal Trade Commission
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.